Background The aim of this study is to explore the off-label usage of targeted therapies (TTs) for patients with osteosarcoma registered inside the French Sarcoma Group C Bone Tumor Research Group (GSF-GETO) nationwide registry. in comparison to various other TTs (Threat Proportion (HR)?=?2.7, 95?% CI [1.05C7.1]). No dangerous loss of life was reported. Rabbit polyclonal… Continue reading Background The aim of this study is to explore the off-label